Industry
Grow Pharma to distribute Spectrum Therapeutic’s medical cannabis products in UK
Spectrum Therapeutic’s UK product range includes flower and oil formulations.
Estimated reading time: 4 minutes
Grow Pharma has signed a deal with Spectrum Therapeutics, to distribute the firm’s range of GMP-certified cannabis medicines in the UK.
Spectrum Therapeutics is part of the family of brands under Canopy Growth, one of the world’s largest cannabis companies.
Spectrum’s UK product range includes flower and oil medicine formulations which will now be added to Grow’s extensive formulary of cannabis medicines.
Isidore Duru, commercial director, Spectrum Theraputics
Isidore Duru, the recently appointed commercial director for Spectrum Therapeutics in the UK, said: “Working with the Grow Pharma team will broaden our reach and help us provide access to our expanding product portfolio.”
Grow Pharma is market-leading with the widest range of cannabis medicines in the UK which now includes over 25 cannabis flower medicines, 30 oils, capsules and vape cartridges and over 65 medicines in total.
Catering to over 2,500 patients, Grow prides itself on being able to offer all high-end brands available in the UK from the world’s leading licensed producers to doctors and patients. Spectrum’s medicines will sit alongside world renowned producers such as Aurora, Tilray, Columbia Care and Althea.
Grow Pharma is a joint venture between IPS Pharma, an established pharmacy distributor with a track record of fast and efficient distribution of unlicensed “specials” medicines, and Grow Group, a British scale-up comprised of a family of companies all focused on unlocking the medical potential of the cannabis plant for the benefit of patients.
Patient access lead, Alex Fraser
Grow Pharma’s work helps increase education and awareness of cannabis medicines with healthcare professionals so they can include cannabis medicines in their toolbox of options to help improve patients’ lives.
“It’s so important to have a wide range of medicines for the many different patients we see benefitting from cannabis medicines,” said Grow Pharma’s patient access lead, Alex Fraser.
“Cannabis medicines act on the endocannabinoid system, which helps to modulate various bodily functions and mediate a wide range of symptoms in multiple disease areas.
“Bringing Spectrum on board helps us cater to any patient need. It’s a testament to our leading role in this field that the most renowned producers are choosing Grow Pharma as their partner in the UK and working with the family of companies under Grow to help patients live better lives.”
Patients can access cannabis medicines by self-referring to one of the many private clinics.
There are now 15 clinics in the UK set up to prescribe cannabis medicines for patients with a wide range of diseases and symptoms including chronic pain, psychiatric and neurological conditions.
Industry
CBD by British Cannabis™ launches in Selfridges
The brands collection of 100 per cent cannabis supplements will be available in one of the UK’s most famous premium-retailers.
British Cannabis™ has launched its collection of 100 per cent cannabis supplements and cosmetics in one of the UK’s most famous premium-retailers.
From today (Monday 4 July) the full range of CBD by British Cannabis™ products debuts in Selfridges London at the new Feel Good Bar, located in the Beauty Hall, as well as online.
Since launching seven years ago, British Cannabis™ (listed as CBD Health Foods Ltd) has experienced exceptional demand for its high quality and great tasting CBD products.
Today, the company is to launch their premium, flagship range in Selfridges.
The CBD by British Cannabis™ collection will be showcased in the Beauty Hall at Selfridges London, a place to discover products that spark innovative wellbeing practices and thought-provoking ideas and home to world-leading brands.
CBD by British Cannabis™ products have won multiple awards in recent years, including the Highly Commended 2021, P3 MVP Award for 1000mg CBD Cannabis Oils, ICP magazine’s 2022 CBD Product of The Year, and Your Healthy Living magazine’s 2022 Silver Award for Best CBD Products (for CBD by British Cannabis™ Dermal Patches 500mg).
All of the food supplement products in the CBD by British Cannabis™ collection are included on the Food Standards Agency’s public list of products that are legal for sale on the UK market via the successful submission of British Cannabis’™ Novel Foods applications.
A recent update by the governments Food Standards Agency saw British Cannabis™ ranked as the UK’s largest CBD manufacturer by number of publicly listed CBD products manufactured.
Read more industry news at Cannabis Wealth
More than just CBD – The British Cannabis™ Story
CBD by British Cannabis™ is not ‘just CBD’; these 100 per cent cannabis products contain hundreds of other beneficial cannabis compounds, terpenes, flavonoids, phenols and more.
All of these natural elements and yet still being compliant with regulations and legal for sale within the UK. Each product is rigorously tested for accuracy, purity, and THC-free status for consumer peace of mind.
Every product contains the knowledge and expertise that has been amassed over the last seven years of British Cannabis™ existence, evidenced in the growing, extraction, research, development, and manufacturing that saw this British start-up grow to be the leading authority in consumer cannabis products within the UK.
British Cannabis™ CEO, Thomas Whettem, celebrated the news, commenting: “This is yet another great milestone in the British Cannabis™ story. It is a testament to the levels of excellence we demand within our supply chain and products, that we are now stocked at an iconic, prestige retailer in Selfridges.
“We set out to create ‘the champagne of CBD oils’, with more beneficial cannabis phytochemicals than any other CBD products compliant and legal for sale today. Our premium, THC-free products are both UK-born and UK-manufactured, thus debuting in Selfridges London seems very appropriate.”
British Cannabis™ launched a television campaign in March 2022 for its premium flagship range, CBD by British Cannabis™, as part of a half a million pound investment in awareness building and consumer recruitment 2022/23.
Set in the style of a classic health and beauty advert, the creative aimed to break down barriers to legal cannabis-derived products, gaining broadcaster approval to make more industry-specific references than any campaign to date.
Shown across dozens of premium channels on the SKY and Channel 5 networks, this marked the first time that the SKY network had opened its doors to CBD advertisers on their linear stations since 2019.
British Cannabis™ Managing Director, David Ralson, said: “As proud as we are of our tested, trusted, super-premium CBD supplements and cosmetics, we are equally proud to now be bringing them to the world-class shopping experience at Selfridges, as part of our distribution expansion plans.
“For over a century, Selfridges have brought premium health and beauty products to the forefront in exciting ways – and especially in their new Feel Good Bar. As one of the UK’s original British-made CBD ranges, with a heritage in this young industry of nearly seven years, the match of Selfridges and CBD by British Cannabis™ seems a perfect fit.
“I hope that Selfridges shoppers grow to love and trust our CBD range as much as our existing loyal customer base, who over the years have given us over 1,500 5-star reviews on Trustpilot.”
BRITISH CANNABIS™ can be reached on +44 (0) 203 965 2420 or via email at [email protected]
Find us on LinkedIn – Search ‘BRITISH CANNABIS’ or search ‘@BritishCanna’ for Facebook and Twitter.
Industry
New fully digital cannabis dispensary launches in UK
It aims to streamline the process through which cannabis patients can access their medicine.
A new fully digital medical cannabis pharmacy aims to improve the dispensing experience for UK patients.
A new digital dispensing solution has launched in the UK, with the aim of streamlining the process through which cannabis patients can access their medicine.
Through the new system, patients are able to schedule delivery to their home or office, with a 120-minute delivery service in London and Birmingham and next-day delivery across the UK.
Akanda subsidiary, CanMart, has partnered with digital pharmacy infrastructure Phlo Connect and Cellen Life Sciences to bring the project to life.
The process will be increasingly seamless for patients in the near future as Phlo Connect, Cellen and CanMart build additional digital interconnections, Akanda said.
Tej Virk, CEO of Akanda, said: “Akanda is committed to expanding access to high-quality products for anyone in need, and that is qualified in the United Kingdom, a growing market for medical cannabis.
“Phlo Connect and Cellen are the ideal partners to make this happen, combining the UK’s first fully digital pharmacy with a digital dispensing model that is easy to use, secure, and real-time.
“In the nascent UK medical cannabis market, patients currently suffer from excess friction as the prescription process, and last-mile delivery is disjointed.
“We firmly believe that our solution is the best way to satisfy patients and get our 1P and 3P-supplied medical cannabis in their hands quickly and conveniently, which will greatly improve the patient experience.”
The partnership with Phlo Connect builds on CanMart’s existing partnership with Cellen, a health tech company that provides treatment to chronic pain patients through Leva Clinic, as well as through partners including the NHS, and Boots UK.
The Leva Clinic, which is licensed and regulated by the Care Quality Commission, is one of the first fully digital pain clinics in the UK.
Cellen is also a medical cannabis supplier to Project Twenty21, the large-scale medical cannabis observational study monitored by Drug Science that aims to improve access to medical cannabis.
Adam Hunter, CCO of Phlo Connect commented: “We believe partnering with CanMart and Cellen will be a game-changer for medicinal cannabis patients here in the UK.
“By integrating with both CanMart and Cellen via our API-driven pharmacy platform, we believe that this partnership is the first truly end-to-end digital experience for medicinal cannabis patients in the UK.”
He added: “Our patients require access to new high-quality products without the friction and hassle of traditional dispensing services. This partnership is another example of our continuing efforts to build on our national, established relationships with the wider pharmaceutical community in innovative ways.
“We believe that CanMart’s access to high quality products as well as Phlo Connect’s extensive capabilities in dispensing will go a long way to helping our service to our patients.”
Industry
CiiTECH celebrates five years with five days of CBD offers
CiiTECH’s five-year birthday is a pivotal moment, the company said.
Cannabis healthcare company CiiTECH celebrates its fifth birthday and reflects on a turbulent half-decade for the CBD industry.
CiiTECH’s five-year birthday is a pivotal moment, the company said. After what has been one of the most turbulent times for the industry, the firm has achieved six months of stability. With new crypto projects on the horizon and new markets on the cards, the company is gearing up for a period of growth.
CBD is a tough industry to be in right now but that has never stopped CiiTECH CEO and founder, Clifton Flack, from driving the business through regulatory issues and the challenges of an increasingly saturated market.
“When we started the business in 2017 the market was approaching the peak of interest and excitement. Since then, alongside the hundreds of brands that have been born to compete with us, we’ve also faced monumental regulatory pressures and flip-flopping,” Flack said.
“We’re still here though, independent and with a bright future ahead as the coming year ahead brings settled regulations.”
After a stormy start to the year, the FSA delivered on their promise to roll out a framework by which products can be set on a supervised pathway to novel food authorisation. The market is now more difficult than ever to penetrate for new and emerging brands, however it gives established UK CBD companies like CiiTECH an advantage over international companies attempting to penetrate the UK market.
“In parallel, the industry and our peers have had a two year pandemic, Brexit supply chain disruptions and now a cost of living crisis set to put all previous volatilities to shame,” Flack added.
“Now more than ever, cannabis healthcare companies need to take our time, avoid the panic and focus on delivering quality products behind trusted brands that are built for the long term.”
Recently, CiiTECH investigated a stock market listing on the London Stock Exchange but the IPO did not come to fruition.
“As the CEO, I had to make an impossible decision,” Flack said.
“Amongst other things, the timing was just not right. Consumer sentiment and demands are volatile and we found the essence of our company getting lost in bureaucracy at a time when it should have been front of mind.
Yesterday, CiiTECH launched five promotions over five days to celebrate the anniversary of the company.
“As a revenue-driven business, CiiTECH would not be in the position it is today without its army of loyal Provacan customers, so we’re giving back to them the best way we know-how.
“With five days’ worth of promos and freebies to mark five years of success. Our Friday promo emails have become somewhat legendary among our customers but we have never done anything like this before.”
News2 years agoCommunity extends support to cannabis icon Rick Simpson
News2 years agoCancer survivor claims cannabis oil helped her beat brain tumour
Case Studies2 years agoCBD oil and fibromyalgia – a case study
News2 years agoNHS lines up cannabis medicine manufacturing
News2 years agoLiving with chronic fatigue – my CBD story
News1 year agoUK grants second licence to grow high-THC medical cannabis
Insight2 years agoI’ve gone from a wheelchair to walking thanks to cannabis
Feature2 years agoMedical cannabis could help long-term effects of COVID-19, says David Nutt
